Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
This paper reviews the clinical profile of aprepitant, the first neurokinin-1 (NK(1)) receptor antagonist to be approved for use in the prevention of chemotherapy-induced nausea and vomiting. When given to patients receiving highly emetogenic chemotherapy, aprepitant in combination with a 5-hydroxytryptamine type-3 (5HT(3)) receptor antagonist and a corticosteroid provides significantly improved protection from chemotherapy-induced nausea and vomiting over that which has been previously achievable with current antiemetics.
Pendergrass
Kelly
K
Kansas City Cancer Center - South, 1000 East 101st Street Terrace, Kansas City, Missouri 60131, USA. kelly.pendergrass@usoncology.com
Hargreaves
Richard
R
Petty
Kevin J
KJ
Carides
Alexandra D
AD
Evans
Judith K
JK
Horgan
Kevin J
KJ
D000284:Administration, Oral; D000932:Antiemetics / Q000494:pharmacology / Q000627:therapeutic use*; D000077608:Aprepitant; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D009025:Morpholines / Q000494:pharmacology / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced* / Q000517:prevention & control*; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1 / Q000008:administration & dosage / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
D000932:Antiemetics; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D000077608:Aprepitant